Forest Laboratories — Proxy Contest (July 2011)
34 slides from Forest Laboratories's proxy contest presentation, Jul 28, 2011
Slide 1: Forest Labs: A Leading Pharma Company
Forest Labs A Leading Pharma Company July 2011
Slide 2: Attendees
Attendees Howard Solomon, CEO Ken Goodman, Lead Director Chris Coughlin, Director Nominee Gerald Lieberman, Director Nominee Lester Salans, Director Nominee Elaine Hochberg, EVP and Chief Commercial Officer Frank Perier, EVP Finance and Administration and Chief Financial Officer David Solomon, SVP C
Slide 3: Forest Has Grown & Transformed Its Business
Forest Has Grown & Transformed Its Business Management and Board of Directors have led the growth and evolution of Forest into one of the top 12 branded pharma companies in America by market cap — Transformed the company multiple times: from initial focus on vitamins and generics, to focus on contro
Slide 4: Forest — A Leading Pharma Company
Forest — A Leading Pharma Company Forest is one of the top 12 branded pharma companies in America by market cap (1) — Track record of financial performance with revenue of $4.4Bn (2) — Commercial success leading to four $1Bn+ blockbuster products in CELEXA, LEXAPRO, BENICAR ® and NAMENDA (3) — Share
Slide 5: Track Record of Financial Performance
Track Record of Financial Performance (1) Over the last 10 years, Forest has increased revenue at a compound annual growth rate of 12.1% — Commercial success has grown four products, CELEXA, LEXAPRO, BENICAR ® and NAMENDA, to blockbuster status with over $1Bn in sales Over this same time period, our
Slide 6: Delivering Shareholder Returns in Short and Long Term
Delivering Shareholder Returns in Short and Long Term Management team has excellent track record of Price Performance (1)(2)(3) As of June 30, 2011 creating shareholder value Forest S&P 500 DRG CEO Howard Solomon is one of only 8 CEO’s with 1 Year 43.4% 28.1% 20.3% — FRX Outperformance / 15.3% 23.1%
Slide 7: Operational Success Over Time
Operational Success Over Time Has built significant product portfolio over time with four blockbuster products — Successfully managed CELEXA Loss of Exclusivity through development of LEXAPRO — Now focused on upcoming LEXAPRO and NAMENDA Loss of Exclusivity Management efforts over the last eight yea
Slide 8: Operational Success Over Time (cont'd): NME Approvals
Operational Success Over Time (cont’d) Forest has received 7 New Molecular Entities approvals over the last ten years and 4 in the last five years — outperforming many of its largest rivals NME + New BLA Approvals (1)(2)(3)(4)(5) 16 16 12 12 10 9 9 8 8 7 7 Peer Last 10 yrs Median: 7 5 4 4 4 2 2 2 2
Slide 9: Operational Success Over Time (cont'd): Product Launches
Operational Success Over Time (cont’d) 3 products already launched in 2011, 2 products to be launched in 2012 and two more in 2013 — 6 additional products in Phase II/III pipeline will launch in 2014 and beyond 2011 Product Launches + NDA + Ph. III / FY2011 Sales ($Bn) (1) x 2.0 1.6 1.5 1.1 1.0 1.0
Slide 10: Disciplined and Productive Business Development
Disciplined and Productive Business Development Long-standing relationships and commercial success have made Forest a partner of choice — Numerous repeat partnership agreements with select FY11 Revenue: $2.3Bn companies Track record of success with all forms of licensing and partnership arrangements
Slide 11: Nine New Products to Launch 2008-2013
Nine New Products to Launch 2008-2013 “Next Nine” products are evidence of Forest management’s success in creating a sustainable pharma business Acquisition / Product Indication Sales Force Focus Launch Date Partner License Date Recent Launches BYSTOLIC Hypertension PCP / Cardiologist 2008 2006 Myla
Slide 12: "Next Nine" Products Drive Growth & Diversify Revenue
“Next Nine” Products Drive Growth & Diversify Revenue New products will diversify Forest’s revenue mix significantly and allow a return to growth post the FY2012 Loss of Exclusivity of LEXAPRO — Top line sales growth goals of approximately 10% CAGR (‘13-’17); adjusted EPS growth goals of approximate
Slide 13: Maximizing Product Potential
Maximizing Product Potential Lineage of delivering blockbuster products to competitive U.S. primary care space Not a single product story; Forest has repeatedly demonstrated commercial success with CELEXA, LEXAPRO, NAMENDA, and BENICAR ® , among others — CELEXA was 5th SSRI launched into market and
Slide 14: Blockbuster Small Molecule Products Face LOE Cliffs
Blockbuster Small Molecule Products Face LOE Cliffs Small molecule drugs rapidly lose sales post Loss of Exclusivity — Typical drug will lose 90% of branded sales within six months of loss of exclusivity — 7-9 generic competitors are typical for small molecule drugs that have significant branded sal
Slide 15: Successful Management of LOE Cycle: CELEXA
Successful Management of LOE Cycle: CELEXA Forest overcame its first Loss of Exclusivity cycle by successfully replacing CELEXA sales with LEXAPRO sales — a one for one replacement strategy Combined sales increased through CELEXA loss of exclusivity in FY2005 Total CELEXA & LEXAPRO Sales Fiscal Year
Slide 16: Successful Management of LOE Cycle (cont'd)
Successful Management of LOE Cycle (cont’d) Because of the tremendous success in building these franchises, the upcoming Loss of Exclusivity of LEXAPRO and NAMENDA are significant events for Forest Forest has understood and planned for this event for 8 years — will be a nine for two replacement stra
Slide 17: Sales Spend In-Line with Peers with Focus on Productivity
Sales Spend In-Line with Peers with Focus on Productivity Managing business for balance of top-line growth and strong cash flow generation “Best in class” financial metrics for a company with a large primary care footprint — Revenue / Employee compares favorably to peers — SG&A spend in line with pe
Slide 18: Disciplined and Effective R&D Effort
Disciplined and Effective R&D Effort Focused R&D effort with emphasis on productivity and clinical success — R&D spend in line with peers — R&D has been extremely productive as evidenced by five recent product approvals — All product candidates successfully advanced in clinical development in FY2011
Slide 19: Efficient Deployment of Capital
Efficient Deployment of Capital Record of judicious use of cash resources to facilitate growth of business and return capital to shareholders — $2.8Bn invested in business development since 2007 — $2.1Bn on four cash acquisitions and $700MM on initial new product licensing agreements — $1Bn since 20
Slide 20: Management & BOD Ownership Above that of Peers
Management & BOD Ownership Above that of Peers Forest management is focused on building a Ownership by Directors and Executive Officers as a % of Total Shares Outstanding (1)(2)(3) durable and sustainable pharmaceutical company % that delivers strong shareholder returns Forest Warner Chilcott Manage
Slide 21: Management & BOD Incentives In-line with Stockholders
Management & BOD Incentives In-line with Stockholders Compensation for top executives weighted towards % of Stock + Options / Total Compensation for stock and options Top Executives (Average 2004 — 2010) (1)(2)(3) % Forest 69.5 Overall compensation of top executives is similar in Cephalon 73.8 mix t
Slide 22: CEO Compensation Levels Below Those of Peers
CEO Compensation Levels Below Those of Peers Forest median compensation for CEO is below that of business and proxy peers median over last seven years Forest BOD has appropriately increased and decreased compensation for CEO in-line with operating performance of Company — FY09-11 increase in revenue
Slide 23: Enhancing Forest's Board of Directors
Enhancing Forest’s Board of Directors Six of ten proposed directors are newly appointed within the last five years — Three new directors previously added: Nesli Basgoz, Lawrence Olanoff and Peter Zimetbaum Proposing three new directors in 2011 Annual Meeting: — Chris Coughlin, 59, most recently serv
Slide 24: Succession Planning
Succession Planning Pursuant to Forest’s board-driven succession planning process, in November 2010 the Company announced a reorganization of its executive management team Four senior executives were promoted to report directly to Forest’s CEO, each with strong knowledge of Forest’s business — Elain
Slide 25: Addressing Uncertainty over HHS-OIG Investigation
Addressing Uncertainty over HHS — OIG Investigation Top 20 Pharma S&M Practice Settlements Company settled with DOJ and U.S. District $MM Attorney for Massachusetts in September 2010 Pfizer (‘04, ‘07, ‘09) 2,760 related to sales and marketing practices Eli Lilly (‘05, ‘09) 1,460 JNJ (Pending, ‘10) 1
Slide 26: Forest — A Leading Pharma Company
Forest — A Leading Pharma Company Forest has grown from a $5MM revenue company in 1977 to a $4.4Bn revenue company in FY11 — Delivered strong shareholder returns in both short and long-term Success with blockbuster products has created Loss of Exclusivity issues that many big pharmas face — Successf
Slide 27: Q1 Earnings Favorable Sell-Side Response
Q1 Earnings Favorable Sell-Side Response Financial Performance — “The company maintained upbeat expectations for its key products, noting the shift in SG&A resources towards the recently launched products — VIIBRYD, TEFLARO and DALIRESP.” (Ronny Gal, Bernstein Research, 19-Jul-2011) — “..having too
Slide 28: History of Icahn's Interaction with Forest
History of Icahn’s Interaction with Forest Carl Icahn took initial position in Forest stock on August 21, 2009 and in the almost two- year period between then and June 10, 2011, Mr. Icahn did not attempt to contact Forest in any way to express concerns about the Company On June 9, 2011, Forest recei
Slide 29: Director Bios: Howard Solomon
Director Bios Howard Solomon Director since 1964 — Mr. Solomon, 83, is Chairman, Chief Executive Officer and President of Forest. He began his career as an attorney at leading law firms in New York and joined Forest in 1964 as a director and secretary of the Board while serving as outside counsel fo
Slide 30: Director Bios: Christopher J. Coughlin
Director Bios Christopher J. Coughlin 2011 Director Nominee — Mr. Coughlin, 59, most recently served as Executive Vice President and Chief Financial Officer of Tyco International from 2005 to 2010 and remains an advisor to Tyco. During his tenure, he played a central role in the separation of Tyco i
Slide 31: Director Bios: Kenneth E. Goodman
Director Bios Kenneth E. Goodman Director since 1998 — Mr. Goodman, 63, is the former President and Chief Operating Officer of Forest, a position that he held from 1998 to 2006. For eighteen years prior thereto, Mr. Goodman served as Forest’s Vice President, Finance and Chief Financial Officer and w
Slide 32: Director Bios: Lawrence S. Olanoff
Director Bios Lawrence S. Olanoff, M.D., Ph.D. Director since 2006 — Dr. Olanoff, 59, served as Forest’s Chief Operating Officer from 2006 to 2010 and currently serves as Senior Scientific Adviser to the Company. From July 2005 to October 2006, Dr. Olanoff was President and Chief Executive Officer a
Slide 33: Director Bios: Brenton L. Saunders
Director Bios Brenton L. Saunders 2011 Director Nominee — Mr. Saunders, 41, has been the Chief Executive Officer of Bausch + Lomb and a board director since March 2010. Previously, Mr. Saunders served as a senior executive with Schering-Plough from 2003 to 2010, most recently as President of Global
Slide 34: Important Additional Information & Forward Looking Information
Important Additional Information & Forward Looking Information This document contains quotes and excerpts from certain previously published material. Consent of the author and publication has not been obtained to use the material as proxy soliciting material. Forward Looking Information — Except for